The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction
ConclusionsWe developed a mouse model that recapitulates the human HFpEF disease, providing a novel opportunity to study disease pathogenesis and the development of enhanced therapeutic approaches. We furthermore show that attenuation of cardiometabolic dysregulation may represent a novel therapeutic target for the treatment of HFpEF.
Source: Cardiovascular Research - Category: Cardiology Source Type: research
More News: Cardiology | Cardiovascular | Dapagliflozin | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Diets | Eating Disorders & Weight Management | Endocrinology | Forxiga | Heart | Heart Failure | High Fat | Nutrition | Obesity | Sodium | Study | Victoza